Advertisement

Topics

First-Line Lung Cancer Data and Other New Research from Merck’s Broad Oncology Program to be Presented at AACR Annual Meeting

18:30 EDT 14 Mar 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Late-Breaker Presentation of Overall Survival and Progression-Free Survival Results from Pivotal Phase 3 KEYNOTE-189 Trial with KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy in First-Line Treatment of Adva...

Other Sources for this Article

Merck
Media:
Pamela Eisele, 267-305-3558
or
Courtney Ronaldo, 908-740-6132
or
Investors:
Teri Loxam, 908-740-1986
or
Michael DeCarbo, 908-740-1807

NEXT ARTICLE

More From BioPortfolio on "First-Line Lung Cancer Data and Other New Research from Merck’s Broad Oncology Program to be Presented at AACR Annual Meeting"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...